Cognition Therapeutics Inc. (CGTX) is a clinical stage, biopharmaceutical company dedicated to improving the lives of patients with neurodegenerative disorders. The company is primarily focused on Alzheimer's disease, a devastating condition that has yet to find any long-lasting treatment or cure. CGTX’s mission revolves around halting the progression of neurodegenerative diseases, thereby providing a quality life for patients while also reducing the healthcare burden on families, and society as a whole.
Founded in 2007 and headquartered in Pittsburgh, Pennsylvania, the company leverages an internal and external network of scientific, clinical and business expertise, driving its dedication to bettering human health. It's an entrepreneurial venture that adopts a rigorous, science-led, and patient-focused approach to discover and develop novel therapeutics.
One of its leading drug candidates is CT1812, a proprietary, disease-modifying therapeutic designed to halt the toxic cascades induced by Aβo. The first-in-patient clinical proof of mechanism study (Elayta) for CT1812 is currently being conducted across several hospitals and clinics in the US. Findings from this study have shown that CT1812 can decrease brain amyloid levels, improve memory and cognition, and stabilize daily function in Alzheimer's patients.
CT1812 is not CGTX's sole focus. The company has other potent clinical and pre-clinical product candidates within its pipeline, including CT831 for dementia with Lewy bodies, a progressive brain disorder, and CT854 for PTSD-related cognitive impairment. CGTX believes the combination of its unique research approach, deep clinical development expertise, and strong IP protection places it in the best position to deliver breakthrough therapies for patients suffering from debilitating neurological disorders.
The company listed on the NASDAQ stock market, under the ticker symbol of "CGTX", on January 29, 2021. CGTX operates as a full-blown pharmaceutical company, with duties covering clinical development, intellectual property, finance, human resources, marketing, regulatory interactions, and sales. All these are conducted to the highest standards, with patient welfare and interests at the heart of their operations.
Their dedication to groundbreaking research in the field of Alzheimer's and other neurodegenerative disorders makes them a company poised to contribute significantly to medical science and society. Looking forward, CGTX continues to strive for new discovery and development, with patient benefit the ultimate goal. Their work represents hope for millions of people living with neurodegenerative disorders worldwide.